Drug Approval | June 14, 2022
FDA accepts application for Merck’s Keytruda as adjuvant therapy for Stage IB-IIIA lung cancer
Acceptance based on results from the phase 3 KEYNOTE-091 trial
Acceptance based on results from the phase 3 KEYNOTE-091 trial
Group 4 Medulloblastoma is a rare disease that mostly affects pediatric patients, in which aberrant SRC signaling was identified as a hallmark of the disease
India’s first oncology laboratory for comprehensive Cancer Diagnostic services
Amarex Clinical Research guides its client to phase II of FDA trials
The production and supply in Canada are designed to address the growing need for no-carrier-added Lutetium-177 (n.c.a. Lu-177) in North America
Tislelizumab is now approved in nine indications in China
Centre of Excellence at Kharel comprises Skill-building Centre and Primary, Secondary and Higher Secondary schools
TAK-003 is currently undergoing regulatory review for potential licensure in both the European Union
Company hires life science veteran Jessica Cao to join management team
Marinus has broadened inclusion criteria in the RAISE trial to allow for enrollment of patients previously treated with IV anesthesia.
Subscribe To Our Newsletter & Stay Updated
